Status:
RECRUITING
Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Low Risk
Papillary Thyroid Cancer
Eligibility:
All Genders
18+ years
Brief Summary
To track the outcomes of patients who have been treated with RFA and its long-term effectiveness, and to learn more about the quality of life of patients who have received RFA in this study.
Detailed Description
Primary Objectives • To evaluate thyroid nodule volume changes over time in participants undergoing RFA as part of clinical care Secondary Objectives * To establish the health-related quality of li...
Eligibility Criteria
Inclusion
- Eligibility Criteria
- Participants scheduled to undergo ultrasound-guided RFA for the following conditions: benign thyroid nodules, indeterminate thyroid nodules, low-risk DTC, and recurrent PTC
- Participant is over 18 years and is either not a surgical candidate or has declined surgery.
- Capable and willing to provide written informed consent
- Participant has one of the following diagnoses:
- Biopsy-proven benign thyroid nodules causing compressive and/or cosmetic symptoms who are requesting treatment,
- Biopsy-proven indeterminate nodules (AUS or follicular neoplasm)
- Papillary thyroid carcinoma (PTC) without metastasis
- Locally recurrent thyroid cancer (\< 2 cm).
- Exclusion Criteria
- Participants meeting any of the following criteria will be excluded:
- Participants considered unsuitable for RFA by the treating physician
Exclusion
Key Trial Info
Start Date :
February 4 2026
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2030
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT07140757
Start Date
February 4 2026
End Date
December 31 2030
Last Update
August 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MD Anderson Cancer Center
Houston, Texas, United States, 77030